Immunotherapy for small-cell lung cancer
Mené sur 216 patients atteints d'un cancer du poumon à petites cellules en progression, cet essai multicentrique de phase I/II évalue l'efficacité, du point de vue du taux de réponse objective, et la toxicité du nivolumab seul ou en combinaison avec l'ipilimumab
Small-cell lung cancer (SCLC) is a subtype of aggressive lung cancer with a poor prognosis. It needs more effective treatments, particularly for recurrent disease. Unfortunately, only one drug (topotecan) has been approved in the second-line setting, with disappointing efficacy; responses were seen in only 7% of patients, disease control in 51%, and time to progression was 16·3 weeks. Recently, immunotherapy with immune-checkpoint inhibitors (nivolumab and pembrolizumab) has been approved by the US Food and Drug Administration and the European Medicines Agency for non-small-cell lung cancer (NSCLC), melanoma, and renal-cell carcinoma.